Dr. Binod Dhakal, MD
Claim this profileMedical College of Wisconsin
Expert in Multiple Myeloma
Expert in Plasma Cell Neoplasm
16 reported clinical trials
26 drugs studied
Area of expertise
1Multiple Myeloma
Global LeaderSerum M-protein (SPEP)
Urine M-protein (UPEP)
Serum free light chain (FLC) assay
2Plasma Cell Neoplasm
Global LeaderSerum M-protein (SPEP)
Urine M-protein (UPEP)
Serum free light chain (FLC) assay
Affiliated Hospitals
Clinical Trials Binod Dhakal, MD is currently running
CFT7455
for Lymphoma
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Recruiting1 award Phase 1 & 210 criteria
Iberdomide Combo
for Multiple Myeloma
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administration, and compelling single agent activity even in heavily pretreated MM, iberdomide is likely amenable to long term therapy in patients with high-risk of relapse/progression identified by the persistence of MRD(+). The investigators intend to develop combination(s) of iberdomide with other agents with complementary mechanism of action in the consolidation setting post AHCT in order to achieve and sustain MRD (-).
Recruiting3 awards Phase 1 & 214 criteria
More about Binod Dhakal, MD
Clinical Trial Related4 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Binod Dhakal, MD has experience with
- Dexamethasone
- Bortezomib
- Isatuximab
- Pomalidomide
- Lenalidomide
- Daratumumab
Breakdown of trials Binod Dhakal, MD has run
Multiple Myeloma
Plasma Cell Neoplasm
Kidney Failure
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Binod Dhakal, MD specialize in?
Binod Dhakal, MD focuses on Multiple Myeloma and Plasma Cell Neoplasm. In particular, much of their work with Multiple Myeloma has involved Serum M-protein (SPEP) patients, or patients who are Urine M-protein (UPEP).
Is Binod Dhakal, MD currently recruiting for clinical trials?
Yes, Binod Dhakal, MD is currently recruiting for 5 clinical trials in Milwaukee Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Binod Dhakal, MD has studied deeply?
Yes, Binod Dhakal, MD has studied treatments such as Dexamethasone, Bortezomib, Isatuximab.
What is the best way to schedule an appointment with Binod Dhakal, MD?
Apply for one of the trials that Binod Dhakal, MD is conducting.
What is the office address of Binod Dhakal, MD?
The office of Binod Dhakal, MD is located at: Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States. This is the address for their practice at the Medical College of Wisconsin.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.